These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 27180793)

  • 21. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
    Osborne CK; Pippen J; Jones SE; Parker LM; Ellis M; Come S; Gertler SZ; May JT; Burton G; Dimery I; Webster A; Morris C; Elledge R; Buzdar A
    J Clin Oncol; 2002 Aug; 20(16):3386-95. PubMed ID: 12177098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
    Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
    Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
    Howell A; Robertson JF; Quaresma Albano J; Aschermannova A; Mauriac L; Kleeberg UR; Vergote I; Erikstein B; Webster A; Morris C
    J Clin Oncol; 2002 Aug; 20(16):3396-403. PubMed ID: 12177099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [An Elderly Patient with Metastatic Breast Cancer Who Developed Severe Adverse Events such as Stomatitis and Interstitial Pneumonia after Everolimus plus Exemestane Treatment].
    Sakiyama K; Yoshida T; Goto Y; Kimura M
    Gan To Kagaku Ryoho; 2016 Jun; 43(6):753-5. PubMed ID: 27306814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimizing the treatment of metastatic breast cancer.
    Gralow JR
    Breast Cancer Res Treat; 2005; 89 Suppl 1():S9-S15. PubMed ID: 15770536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient database analysis of fulvestrant 500 mg in the treatment of metastatic breast cancer: A European perspective.
    Marchetti P; Maass N; Gligorov J; Berger K; MacDougall F; Montonen J; Lewis J
    Breast; 2017 Apr; 32():247-255. PubMed ID: 28011074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.
    Zaman K; Winterhalder R; Mamot C; Hasler-Strub U; Rochlitz C; Mueller A; Berset C; Wiliders H; Perey L; Rudolf CB; Hawle H; Rondeau S; Neven P
    Eur J Cancer; 2015 Jul; 51(10):1212-20. PubMed ID: 25892646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
    Cristofanilli M; Valero V; Mangalik A; Royce M; Rabinowitz I; Arena FP; Kroener JF; Curcio E; Watkins C; Bacus S; Cora EM; Anderson E; Magill PJ
    Clin Cancer Res; 2010 Mar; 16(6):1904-14. PubMed ID: 20215537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer.
    Smith JW; Vukelja S; Hoffman AD; Jones VE; McIntyre K; Berrak E; Song JX; O'Shaughnessy J
    Clin Breast Cancer; 2016 Feb; 16(1):31-7. PubMed ID: 26433876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
    Robertson JF; Osborne CK; Howell A; Jones SE; Mauriac L; Ellis M; Kleeberg UR; Come SE; Vergote I; Gertler S; Buzdar A; Webster A; Morris C
    Cancer; 2003 Jul; 98(2):229-38. PubMed ID: 12872340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
    Robertson JF; Come SE; Jones SE; Beex L; Kaufmann M; Makris A; Nortier JW; Possinger K; Rutqvist LE
    Eur J Cancer; 2005 Feb; 41(3):346-56. PubMed ID: 15691633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
    Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
    J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A case of recurrent breast cancer with multiple liver metastases responding to combination therapy of capecitabine and MPA].
    Konishi K; Hasegawa N; Kawabata M; Abeshima S; Ichimura T; Kaneko H; Nakayama T
    Gan To Kagaku Ryoho; 2007 Oct; 34(10):1689-91. PubMed ID: 17940392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
    O'connor T; Rustum Y; Levine E; Creaven P
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fulvestrant in advanced breast cancer following tamoxifen and aromatase inhibition: a single center experience.
    Wang J; Jain S; Coombes CR; Palmieri C
    Breast J; 2009; 15(3):247-53. PubMed ID: 19645779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Breast Cancer with Multiple Liver Metastases Successfully Treated with Capecitabine Monotherapy after Failure of Combination Therapy Comprising Bevacizumab and Paclitaxel].
    Ooe A; Suganuma Y
    Gan To Kagaku Ryoho; 2016 Mar; 43(3):349-51. PubMed ID: 27067853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A case of triple negative chest wall recurrent breast cancer treated with capecitabine and docetaxel combination therapy (XT therapy)].
    Sawada Y; Fujii T; Takahashi H; Yokoyama G; Matsubayashi RN; Inoue Y; Uesugi N; Momosaki S; Toh U; Shirouzu K
    Gan To Kagaku Ryoho; 2009 May; 36(5):815-7. PubMed ID: 19461184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
    Martín M; Ruiz Simón A; Ruiz Borrego M; Ribelles N; Rodríguez-Lescure Á; Muñoz-Mateu M; González S; Margelí Vila M; Barnadas A; Ramos M; Del Barco Berron S; Jara C; Calvo L; Martínez-Jáñez N; Mendiola Fernández C; Rodríguez CA; Martínez de Dueñas E; Andrés R; Plazaola A; de la Haba-Rodríguez J; López-Vega JM; Adrover E; Ballesteros AI; Santaballa A; Sánchez-Rovira P; Baena-Cañada JM; Casas M; del Carmen Cámara M; Carrasco EM; Lluch A
    J Clin Oncol; 2015 Nov; 33(32):3788-95. PubMed ID: 26416999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.
    van Kruchten M; de Vries EG; Glaudemans AW; van Lanschot MC; van Faassen M; Kema IP; Brown M; Schröder CP; de Vries EF; Hospers GA
    Cancer Discov; 2015 Jan; 5(1):72-81. PubMed ID: 25380844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine.
    Levin MK; Wang K; Yelensky R; Cao Y; Ramos C; Hoke N; Pippen J; Blum JL; Brooks B; Palmer G; Palma N; Balasubramanian S; Ross JS; O'Shaughnessy J
    Cancer Med; 2015 Aug; 4(8):1289-93. PubMed ID: 25871911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.